Orion Oyj (OTCMKTS:ORINY) Short Interest Up 200.0% in August

Orion Oyj (OTCMKTS:ORINY) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 300 shares, a growth of 200.0% from the August 15th total of 100 shares. Based on an average trading volume of 1,900 shares, the short-interest ratio is currently 0.2 days.

Orion Oyj Price Performance

Orion Oyj stock remained flat at $26.12 during mid-day trading on Friday. 1 shares of the company’s stock traded hands, compared to its average volume of 615. The firm has a market capitalization of $7.37 billion, a PE ratio of 31.10 and a beta of 0.21. The firm’s fifty day simple moving average is $24.14 and its two-hundred day simple moving average is $21.05. The company has a quick ratio of 1.29, a current ratio of 2.39 and a debt-to-equity ratio of 0.31. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $28.44.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.17 EPS for the quarter. Orion Oyj had a net margin of 18.08% and a return on equity of 27.97%. The business had revenue of $332.07 million during the quarter. Equities analysts expect that Orion Oyj will post 1.11 earnings per share for the current year.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.